Myophosphorylase (Pygm) Mutations Determined By Next Generation Sequencing In A Cohort From Turkey With Mcardle Disease
View/ Open
Date
2017Author
Inal-Gultekin, Guldal
Toptas-Hekimoglu, Bahar
Gormez, Zeliha
Gelisin, Ozlem
Durmus, Hacer
Erguner, Bekir
Demirci, Huseyin
Sagiroglu, Mahmut S.
Parman, Yesim
Deymeer, Feza
Yilmaz-Aydogan, Hulya
Pence, Sadrettin
Bekircan-Kurt, Can Ebru
Tan, Ersin
Erdem-Ozdamar, Sevim
Ustek, Duran
Giger, Urs
Ozturk, Oguz
Serdaroglu-Oflazer, Piraye
xmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
This study aimed to identify PYGM mutations in patients with McArdle disease from Turkey by next generation sequencing (NGS). Genomic DNA was extracted from the blood of the McArdle patients (n = 67) and unrelated healthy volunteers (n = 53). The PYGM gene was sequenced with NGS and the observed mutations were validated by direct Sanger sequencing. A diagnostic algorithm was developed for patients with suspected McArdle disease. A total of 16 deleterious PYGM mutations were identified, of which 5 were novel, including 1 splice-site donor, 1 frame-shift, and 3 non-synonymous variants. The p.Met1Val (27-patients/11-families) was the most common PYGM mutation, followed by p.Arg576* (6/4), c.1827+7A>G (5/4), c.772+2_3delTG (5/3), p.Phe710del (4/2), p.Lys754Asnfs (2/1), and p.Arg50* (1/1). A molecular diagnostic flowchart is proposed for the McArdle patients in Turkey, covering the 6 most common PYGM mutations found in Turkey as well as the most common mutation in Europe. The diagnostic algorithm may alleviate the need for muscle biopsies in 77.6% of future patients. A prevalence of any of the mutations to a geographical region in Turkey was not identified. Furthermore, the NGS approach to sequence the entire PYGM gene was successful in detecting a common missense mutation and discovering novel mutations in this population study. (C) 2017 Elsevier B.V. All rights reserved.